Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT00004154
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00027586
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00050986
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2002-11-27
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 603
- Registration Number
- NCT00050167
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2002-11-08
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT00048737
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Therapy of Early Chronic Phase CML With Gleevec
- First Posted Date
- 2002-11-06
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00048672
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
- Conditions
- Interventions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00048100
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00048087
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2002-10-16
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00047710
- Locations
- 🇺🇸
University of Texas MDAnderson Cancer Center, Houston, Texas, United States
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2002-10-09
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00047502
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States